⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17624320 | 0.76 | — | — | |
| SCHEMBL17624319 | 0.72 | — | — | |
| SCHEMBL12179387 | 0.72 | — | — | |
| SCHEMBL17624325 | 0.72 | — | — | |
| SCHEMBL18372217 | 0.72 | — | — | |
| SCHEMBL26692287 | 0.70 | POLB (0.42) | — | |
| SCHEMBL25249441 | 0.69 | GABRA1 (0.32) | — | |
| SCHEMBL12731976 | 0.69 | — | — | |
| SCHEMBL2595337 | 0.69 | — | — | |
| SCHEMBL21718648 | 0.69 | CYP1A2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109715-A1 | IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE | PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) | 2026-04-23 | — | — | US | disclosed |
| EP-4600246-A1 | IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE | Public University Corporation Yokohama City University (JP) | 2025-08-13 | — | — | EP | disclosed |
| WO-2024075696-A1 | IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE | 公立大学法人横浜市立大学 | 2024-04-11 | — | — | WO | disclosed |
| US-11858915-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4273146-A1 | TRICYCLIC COMPOUND AND USE THEREOF | Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-06-29 | — | — | US | disclosed |
| US-20220340576-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
| WO-2022135560-A1 | SUBSTITUTED IMIDAZO[1,5-B]PYRIDAZINE COMPOUNDS AS KINASE INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2022-06-30 | — | — | WO | disclosed |
| WO-2021057975-A1 | MUTANT IDH2 INHIBITOR AND APPLICATION THEREOF | 贝达药业股份有限公司 | 2021-04-01 | — | — | WO | disclosed |
| US-10934302-B1 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| WO-2019183364-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| WO-2016044604-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |